LITESPARK-011 (lenvatinib + belzutifan vs cabozantinib in pretreated clear cell RCC) is positive for PFS. Belzutifan is well tolerated making it a good partner. It’s the 1st positive targeted therapy combo RIII trial in RCC @OncoAlert #UromigosLive https://t.co/E3i1VH6hvy

Landscape of mHSPC with an expert panel! - are we ready to make decisions based on molecular data? - PARPi in a biomarker-selected population? - LuPSMA in this setting? Another heated discussion for the books! @Uromigos @OncoAlert #Uromigoslive

On behalf of a terrific team of investigators (@BGarmezy @KotechaMD @DrKarieRuncie @BraunMDPhD et al), very proud to present the 1st data for XmAb819, a first-in-class ENPP3 x CD3 bispecific in patients with #kidneycancer. We have long needed new targets beyond #VEGF-axis &

Front-line triplets and biomarker-based prospective investigation (OPTIC) are discussed on our latest podcast. https://t.co/L0eXr2sQgp

In muscle-invasive bladder cancer, ctDNA-guided adjuvant atezolizumab improved disease-free and overall survival. Proud to be part of this work, with @tompowles1 and all colleagues, patients, families, and sponsors who made it real. @NEJM @myESMO #ESMO25 @OncoBellmunt

#ESMO25 may be over, but #cancerresearch continues! Dr. Vicky Makker presented 5-year follow-up data from the 309/KEYNOTE-775 study that confirmed the efficacy and safety of lenvatinib & pembrolizumab in advanced #endometrialcancer. @MSKCancerCenter ➡️ https://t.co/xTsc41GIsk

Huge congrats to @tompowles1 on shifting the paradigm in #bladdercancer (& frankly #cancer at large) w #IMvigor011, paving the way ctDNA as a tool for potentially allocating #adjuvant therapy. Bravo also on the simultaneous @NEJM publication!

Strong pragmatic and energizing discussion by @DrRanaMcKay: adjuvant durvalumab signals from RAMPART and how neoadjuvant IO from NESCIO could fit: selection, endpoints, and trial priorities. #ESMO25 #RCC @myESMO @Annals_Oncology @OncLive @OncoAlert @OncBrothers

Day 3 #ESMO25 Highlights: Prostate Ca 1. #PSMAddition: LuPSMA in mHSPC 2. #ENZARD: ADT+XRT+/-Enza 3. #EMBARK: Enza biochem recurrent Prostate Ca 4. #CAPItello281: Abi+/-Capi in PTEN Mesothelioma: 5. #DREAM3R: Durva+Chemo 1L #OncTwitter @OncUpdates @OncoAlert 1/11

#ESMO25 Uromigos Unsung Hero poster award for prostate cancer. Sac-TMT + Pembro in mCRPC shows signals of activity. The contribution of pembro is uncertain. More development of ADCs in CRPC is welcome.

Each slide a masterpiece. It’s clear that @drenriquegrande poured his heart & soul into this talk, full of gorgeous slides (not all of them shown below), with deep insights into mechanisms of resistance to ADCs, paving the way towards rationale for novel tx. #ESMO25

Intriguing timely, relevant data on PRCC genomics in pts with African Ancestry by @mzugman skillful presentation. MET alterations uncommon (10.1%); enriched in African ancestry (42.5% vs 20.8%). No MET exon14 skipping seen. Trial equity + precise MET testing matter. #ESMO25 #RCC

Capitello-281 evaluated Akt inhibitor in PTEN deficient mHSPC. 6000 pts screened to randomize ~ 1K. Modest rPFS benefit, OS immature. Nice to see biomarker approach, TBD if it moves the needle enough to justify the toxicity and identification

Breaking news from #ESMO25👉Improved OS in high risk biochemical recurrent #ProstateCancer on with ENZA+ADT vs ADT alone, HR: 0.59 (no OS benefit with ENZA monotherapy), 👏wonderful news for our pts👉congrats @SFreedlandMD @nealshore & the team. @OncoAlert @urotoday @PCF_Science

A discussion for the record books. @AndreaNecchi provides an amazing overview of considerations (geographic variations in practice, treatment landscape, etc.). Beautiful figures done in collaboration w @NazliDizman, @BrigidaMaiorano et al. Bravo! #ESMO25

PSMA Addition: A randomized phase 3 trial of ARPI +/- 177Lu-PSMA617 in mHSPC 1 PSMA+ PET/CT+ve HSPC showed ⬆️ PFS without OS at this stage (⬆️ cross over). Multiple 1st line options exist (E.g BRCA). Earlier treatment seems effective. Later trials achieved OS. #ESMO25 @OncoAlert

Program Director's Note - What Does it Take to Get an Interview Around Here? A #ProgramDirectorsNote to my @TradIMYale residents. @YaleIMed https://t.co/9FOjyj3eVe

Sophisticated discussion by @Clara__Steiner, who offered great context on #DISCUS (@drenriquegrande), #CM274 (@MattGalsky) & neoadjuvant #GDF15 (@AndreaNecchi), drawing not just from #bladdercancer but other diseases. Excellent session - data from #CM274 a great primer for

#ESMO25 Thank you to the scientific committee for selecting our work for oral presentation: Patient-level analysis of Pneumonitis in Nivo-based regimens for solid tumors: - 11,777pts, 716 with pneumonitis (6.1%) - risk factors: age >65; NSCLC, smoking+, Ipi/nivo (p<0.005) 1/3

The bar is raised! Periop 🥪 EVP for cis ineligible (90%) or refusing (10%) MIBC = new SOC *KN905/EV302* ✅pT0 rate highest ever in MIBC 57% ITT, 65% cystectomy sub-pop ✅2yr EFS & OS on par w DDMVAC in cis eligible -cis eligible EVP🥪 trial *KNB15/EV304* readout awaited #ESMO25